WO1999011758A3 - Cultures of human cns neural stem cells - Google Patents

Cultures of human cns neural stem cells Download PDF

Info

Publication number
WO1999011758A3
WO1999011758A3 PCT/US1998/018597 US9818597W WO9911758A3 WO 1999011758 A3 WO1999011758 A3 WO 1999011758A3 US 9818597 W US9818597 W US 9818597W WO 9911758 A3 WO9911758 A3 WO 9911758A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
neural stem
cultures
human cns
cns neural
Prior art date
Application number
PCT/US1998/018597
Other languages
French (fr)
Other versions
WO1999011758A2 (en
Inventor
Melissa Carpenter
Original Assignee
Cytotherapeutics Inc
Melissa Carpenter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25453045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999011758(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytotherapeutics Inc, Melissa Carpenter filed Critical Cytotherapeutics Inc
Priority to AU93059/98A priority Critical patent/AU758270B2/en
Priority to CA2302484A priority patent/CA2302484C/en
Priority to JP2000508770A priority patent/JP4848538B2/en
Priority to US09/486,302 priority patent/US6498018B1/en
Priority to EP98945920.1A priority patent/EP1007636B1/en
Publication of WO1999011758A2 publication Critical patent/WO1999011758A2/en
Publication of WO1999011758A3 publication Critical patent/WO1999011758A3/en
Priority to US10/713,373 priority patent/US20040103448A1/en
Priority to US11/356,281 priority patent/US20060240553A1/en
Priority to US11/903,408 priority patent/US20080107633A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Abstract

Isolation, characterization, proliferation, differentiation and transplantation of mammalian neural stem cells is disclosed.
PCT/US1998/018597 1997-09-05 1998-09-04 Cultures of human cns neural stem cells WO1999011758A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU93059/98A AU758270B2 (en) 1997-09-05 1998-09-04 Cultures of human CNS neural stem cells
CA2302484A CA2302484C (en) 1997-09-05 1998-09-04 Cultures of human cns neural stem cells
JP2000508770A JP4848538B2 (en) 1997-09-05 1998-09-04 Culture of human CNS neural stem cells
US09/486,302 US6498018B1 (en) 1997-09-05 1998-09-04 Cultures of human CNS neural stem cells
EP98945920.1A EP1007636B1 (en) 1997-09-05 1998-09-04 Cultures of human cns neural stem cells
US10/713,373 US20040103448A1 (en) 1997-09-05 2003-11-13 Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain
US11/356,281 US20060240553A1 (en) 1997-09-05 2006-02-15 Cultures of human CNS neural stem cells
US11/903,408 US20080107633A1 (en) 1997-09-05 2007-09-21 Cultures of human CNS neural stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/926,313 1997-09-05
US08/926,313 US5968829A (en) 1997-09-05 1997-09-05 Human CNS neural stem cells

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US08/926,313 Continuation US5968829A (en) 1997-09-05 1997-09-05 Human CNS neural stem cells
US08/926,313 Continuation-In-Part US5968829A (en) 1997-09-05 1997-09-05 Human CNS neural stem cells

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/486,302 A-371-Of-International US6498018B1 (en) 1997-09-05 1998-09-04 Cultures of human CNS neural stem cells
US10/134,234 Continuation US6777233B2 (en) 1997-09-05 2002-04-29 Cultures of human CNS Neural stem cells
US10/328,644 Division US20030166276A1 (en) 1997-09-05 2002-12-23 Cultures of human CNS neural stem cells

Publications (2)

Publication Number Publication Date
WO1999011758A2 WO1999011758A2 (en) 1999-03-11
WO1999011758A3 true WO1999011758A3 (en) 1999-05-27

Family

ID=25453045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018597 WO1999011758A2 (en) 1997-09-05 1998-09-04 Cultures of human cns neural stem cells

Country Status (6)

Country Link
US (6) US5968829A (en)
EP (1) EP1007636B1 (en)
JP (2) JP4848538B2 (en)
AU (1) AU758270B2 (en)
CA (1) CA2302484C (en)
WO (1) WO1999011758A2 (en)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US5958767A (en) * 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20020168766A1 (en) * 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6468794B1 (en) * 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
EP1900811B1 (en) * 1999-02-12 2010-07-07 StemCells California, Inc. Enriched central nervous system cell populations
US7217565B2 (en) * 1999-02-12 2007-05-15 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US7105150B2 (en) * 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells
US7037719B1 (en) 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
JP2002538820A (en) * 1999-03-17 2002-11-19 ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション Generation and use of uncloned cDNA libraries of microclones
JP2003524396A (en) * 1999-03-18 2003-08-19 ウェルスタット バイオロジクス コーポレイション Cells, cell populations and methods of making and using them.
AU4440000A (en) * 1999-04-30 2000-11-17 Diatranz Limited Xenotransplant for cns therapy
US20090047325A1 (en) * 1999-04-30 2009-02-19 Neurotrophincell Pty. Limited Xenotransplant for cns therapy
US20050265977A1 (en) * 1999-04-30 2005-12-01 Elliott Robert B Xenotransplant for CNS therapy
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
IL147990A0 (en) * 1999-08-05 2002-09-12 Mcl Llc Multipotent adult stem cells and methods for isolation
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
CA2387748A1 (en) * 1999-10-20 2001-04-26 Stem Cells,Inc. Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain
US6878543B1 (en) 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
US20030143737A1 (en) * 1999-12-07 2003-07-31 Monash University Long-term cell-culture compositions and genetically modified animals derived therefrom
AU779273B2 (en) * 1999-12-07 2005-01-13 Monash University Long-term cell culture compositions and genetically modified animals derived therefrom
EP1107003A1 (en) * 1999-12-09 2001-06-13 Trophos Methods for screening compounds active on neurons
AU2913801A (en) * 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US20050042749A1 (en) * 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7455983B2 (en) * 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US7122177B2 (en) * 2000-01-20 2006-10-17 Diabcell Pty Ltd. Preparation and xenotransplantation of porcine islets
AU3499801A (en) * 2000-02-11 2001-08-20 Schepens Eye Res Inst Isolation and transplantation of retinal stem cells
CA2401989A1 (en) * 2000-03-03 2001-09-07 The Walter And Eliza Hall Institute Of Medical Research A method of treatment
JP4889902B2 (en) 2000-03-14 2012-03-07 イーエス・セル・インターナショナル・プライヴェート・リミテッド Method for producing human neural progenitor cells from human embryonic stem (hES) cells, method for producing neurons using the method, method for producing oligodendrocytes or astrocytes
US7011828B2 (en) * 2000-03-14 2006-03-14 Es Cell International Pte. Ltd. Implanting neural progenitor cells derived for human embryonic stem cells
AU2001253425A1 (en) 2000-04-13 2001-10-30 Board Of Regents, The University Of Texas System Treatment of disorders by implanting stem cells and/or progeny thereof into gastrointestinal organs
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US6828145B2 (en) 2000-05-10 2004-12-07 Cedars-Sinai Medical Center Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
KR100903755B1 (en) * 2000-05-17 2009-06-18 제론 코포레이션 Neural progenitor cell populations
US6897061B1 (en) 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US6602680B2 (en) 2000-07-14 2003-08-05 The Regents Of The University Of California Production of gabaergic cells
ATE553766T1 (en) * 2000-10-17 2012-05-15 Diabcell Pty Ltd PREPARATION AND XENOTRANSPLANTATION OF ISLANDS OF LANGERHANS FROM PIGS
IL155728A0 (en) * 2000-11-22 2003-11-23 Geron Corp Tolerizing allografts of pluripotent stem cells
US6921665B2 (en) * 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
US6576464B2 (en) * 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030032179A1 (en) 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom
AU2002220209B2 (en) 2000-12-06 2006-05-25 Robert J. Hariri Method of collecting placental stem cells
AU2002237126A1 (en) * 2001-03-02 2002-09-19 Stem Cell Therapeutics Inc. Use of ovarian hormone for increasing neural stem cell number
US7501231B2 (en) * 2001-03-23 2009-03-10 University Of Ottawa Methods and compositions for cryopreservation of dissociated primary animal cells
JP3763749B2 (en) * 2001-03-28 2006-04-05 独立行政法人科学技術振興機構 Central nervous system progenitor cells that induce synaptogenic neurons in the spinal cord
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
EP1385938A1 (en) * 2001-04-23 2004-02-04 Nsgene A/S Method and culture medium for producing neural cells expressing tyrosine hydroxylase
US7943376B2 (en) * 2001-04-27 2011-05-17 Stem Cell Therapuetics Inc. Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells
WO2002102989A2 (en) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using valproate
WO2002102988A2 (en) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
EP1572879A4 (en) * 2001-06-22 2006-11-15 Univ Texas Method of producing region-specific neurons from human neuronal stem cells
DK1410029T3 (en) * 2001-07-16 2008-01-07 Protein Forest Inc Arrays of buffers for analysis of biomolecules at their isoelectric point
EP1423504B1 (en) * 2001-08-08 2009-09-23 Levesque Biosciences, Inc. Compositions and methods for isolation, propagation, and differentiation of non-embryonic human stem cells and uses thereof
WO2003014320A2 (en) * 2001-08-10 2003-02-20 Cornell Research Foundation, Inc. Telomerase immortalized human neutral stem cells and phenotypically-restricted progenitor cells
WO2003027270A1 (en) * 2001-09-28 2003-04-03 Diabcell Pty Limited Growing xenotransplant material in culture
CA2461715A1 (en) * 2001-10-02 2003-04-10 Becton, Dickinson And Company Proliferation and differentiation of stem cells using extracellular matrix and other molecules
US8153424B2 (en) * 2001-10-03 2012-04-10 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US7588937B2 (en) 2001-10-03 2009-09-15 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US7129034B2 (en) * 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
NZ515310A (en) * 2001-11-07 2004-08-27 Diabcell Pty Ltd Methods of treatment and delivery modes
AU2002334746B2 (en) * 2001-11-15 2007-10-11 Becton, Dickinson And Company Methods and devices for the integrated discovery of cell culture environments
JP2005514926A (en) * 2002-01-14 2005-05-26 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Novel mammalian multipotent stem cells and compositions, methods for their preparation and administration
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20040029269A1 (en) * 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells
US20050101014A1 (en) * 2002-07-11 2005-05-12 Keirstead Hans S. Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US7312025B2 (en) * 2002-07-12 2007-12-25 University Of Washington Methods and systems for extended in vitro culture of neuronal cells
WO2007116408A2 (en) * 2006-04-11 2007-10-18 Nanodiagnostics Israel Ltd. Pluripotent stem cells characterized by expression of germline specific genes
WO2004009758A2 (en) * 2002-07-23 2004-01-29 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
AU2003276924A1 (en) * 2002-09-25 2004-04-19 Bresagen, Inc. Compositions and methods for enrichment of neural stem cells using ceramide analogs
US7427603B2 (en) * 2002-09-26 2008-09-23 The Children's Medical Center Corporation Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
US20040147020A1 (en) * 2002-11-01 2004-07-29 The Regents Of The University Of Colorado, A Body Corporate Dopamine neurons from human embryonic stem cells
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
KR101042448B1 (en) 2002-11-26 2011-06-16 안트로제네시스 코포레이션 Cytotherapeutics, cytotherapeutic units and methods for treatments using them
EP1570052B1 (en) * 2002-12-02 2009-01-21 AnGes MG, Inc. Method for culturing neural stem cells using hepatocyte growth factor
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2003303741A1 (en) * 2002-12-18 2004-09-17 Bresagen, Inc. Compositions and methods for neural cell production and stabilization
AU2004238057B2 (en) 2003-05-16 2009-09-24 Universite Laval CNS chloride modulation and uses thereof
EP1702062A2 (en) * 2003-06-11 2006-09-20 Jan Remmereit Differentiation of stem cells for therapeutic use
EP1641912B1 (en) 2003-06-20 2016-04-27 Axiogenesis Ag Tissue modelling in embryonic stem (es) cell system
WO2004113516A1 (en) * 2003-06-24 2004-12-29 Diabcell Pty Limited Porcine islets cultured with porcine sertoli cells for xenotransplantation
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
WO2005005662A2 (en) 2003-07-08 2005-01-20 Axiogenesis Ag Secreted proteins as markers for cell differentiation
ATE505539T1 (en) * 2003-09-09 2011-04-15 Univ Keio METHOD FOR PROMOTING SURVIVAL AND/OR PROLIFERATION OF A NEURAL STEM CELL AND FOR PROMOTING NEURAL STEM CELL EXTENSION, PROMOTER THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE NEURAL STEM CELL, TESTING METHODS AND SCREENING METHODS
EP1670935B1 (en) * 2003-09-12 2010-12-29 StemCell Technologies Inc. Neural colony forming assay
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
EP1670897A4 (en) * 2003-09-24 2008-02-27 Univ Leland Stanford Junior Igf-1 instructs multipotent adult cns neural stem cells to an oligodendroglial lineage
JP2005139164A (en) * 2003-11-10 2005-06-02 Toudai Tlo Ltd Pharmaceutical composition for treating neuropathy and neurodegenerative disease
WO2005056755A2 (en) * 2003-12-02 2005-06-23 Catholic Healthcare West Compositions and methods for propagation of neural progenitor cells
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
US20050196864A1 (en) * 2004-02-10 2005-09-08 Goldman Steven A. Induction and high-yield preparative purification of mesencephalic dopaminergic neuronal progenitor cells and dopaminergic neurons from human embryonic stem cells
WO2005079250A2 (en) * 2004-02-13 2005-09-01 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
CA2563518C (en) 2004-04-23 2014-09-02 Bioe, Inc. Multi-lineage progenitor cells
GB2414995B (en) * 2004-06-09 2006-11-15 Univ Edinburgh Neural stem cells
DK1645626T3 (en) 2004-09-30 2008-01-21 Reneuron Ltd cell Line
KR101429284B1 (en) 2004-11-17 2014-08-11 뉴럴스템, 인크. Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions
US20090010873A1 (en) * 2004-11-29 2009-01-08 Yeda Research And Development Co. Ltd. Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
WO2006058427A1 (en) 2004-12-01 2006-06-08 Stem Cell Therapeutics Corporation Platelet-derived growth factor-responsive neural precursor cells and progeny thereof
US7018804B1 (en) 2004-12-03 2006-03-28 Orion Biosolutions, Inc. Determination of cell viability and phenotype
US20060121443A1 (en) * 2004-12-03 2006-06-08 Orion Biosolutions, Inc. Determination of cell viability
AU2006203879A1 (en) * 2005-01-04 2006-07-13 Stemcells California, Inc. Methods for the treatment of lysosomal storage disorders
CA2596281A1 (en) * 2005-01-31 2006-08-10 Cognate Therapeutics, Inc. Adipose derived adult stromal cells exhibiting characteristics of endothelial cells
NZ540597A (en) * 2005-06-08 2007-02-23 Neurotrophincell Pty Ltd A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells
JP2008546385A (en) 2005-06-16 2008-12-25 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド Isolated cells and populations containing isolated cells for treating CNS disease
WO2007002086A2 (en) * 2005-06-22 2007-01-04 Geron Corporation Suspension culture of human embryonic stem cells
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
TW200726474A (en) * 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
US20090148417A1 (en) * 2005-07-28 2009-06-11 Brainguard Co., Ltd Carbon nanotubes serving as stem cell scaffold
US8357666B2 (en) * 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
US9095573B2 (en) * 2005-08-01 2015-08-04 University Of Central Florida Research Foundation, Inc. Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble βAPP in tissue or CSF
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
ES2452595T3 (en) 2005-10-13 2014-04-02 Anthrogenesis Corporation Immunomodulation using placental stem cells
WO2007061805A2 (en) * 2005-11-17 2007-05-31 The Cleveland Clinic Foundation Multipotent neural stem cells
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
KR20210122908A (en) 2005-12-29 2021-10-12 안트로제네시스 코포레이션 Placental stem cell populations
EP2422800A3 (en) 2006-03-07 2013-03-06 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
EP2012819A2 (en) * 2006-03-30 2009-01-14 The Research Foundation Of the City university of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
WO2007121443A2 (en) 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
DK2656832T3 (en) 2006-05-11 2019-04-08 Regenics As Compositions for use in wound healing
US20080003676A1 (en) * 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
US20080124276A1 (en) * 2006-07-24 2008-05-29 Lifeline Cell Technology Synthetic cornea from retinal stem cells
CA2661232A1 (en) * 2006-08-31 2008-03-06 The University Of Louisville Research Foundation, Inc. Transcription factors for differentiation of adult human olfactory progenitor cells
US8685720B2 (en) * 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
PL3255061T3 (en) 2006-11-03 2021-12-06 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
AU2007321928A1 (en) 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
US20090136456A1 (en) * 2006-12-22 2009-05-28 Yadong Huang Methods of treating neurodegenerative disorders
DK2120977T3 (en) 2007-02-12 2013-08-12 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US20080213892A1 (en) * 2007-03-02 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Self-renewal of neural stem cells is promoted by wnt proteins
US20080226707A1 (en) * 2007-03-05 2008-09-18 Jill Helms WNT compositions and methods of use thereof
WO2008109320A1 (en) * 2007-03-08 2008-09-12 Sekula Raymond F Jr A method of producing purified neural stem cells and related methods of treating a patient
WO2008134406A1 (en) * 2007-04-25 2008-11-06 The Board Of Trustees Of The Leland Stanford Junior University Ischemia-induced neovascularization is enhanced by hcns-sc transplantation
ATE530638T1 (en) 2007-04-26 2011-11-15 Univ Ramot PLURIPOTENT AUTOLOGOUS STEM CELLS FROM THE ORAL OR GASTROINTESTINAL MUCOSA
CN101835479A (en) * 2007-07-25 2010-09-15 佰欧益有限公司 Differentiation of multi-lineage progenitor cells to chondrocytes
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
EP2028268A1 (en) 2007-08-20 2009-02-25 Université Libre De Bruxelles Generation of neuronal cells from pluripotent stem cells
EP2192916A4 (en) * 2007-08-23 2012-04-04 Univ Leland Stanford Junior Modulation of synaptogenesis
KR101614823B1 (en) 2007-09-11 2016-04-22 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
KR20210022148A (en) 2007-09-28 2021-03-02 안트로제네시스 코포레이션 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US20090090214A1 (en) * 2007-10-04 2009-04-09 Chung Yuan Christian University Method for forming nano-scale metal particles
CN101939362A (en) 2008-01-30 2011-01-05 杰龙公司 Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
WO2009116951A2 (en) 2008-03-17 2009-09-24 Agency For Science, Technology And Research Microcarriers for stem cell culture
CN102083968A (en) 2008-04-07 2011-06-01 纽珀滕索有限公司 Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator
ES2613965T3 (en) 2008-05-09 2017-05-29 Regenics As Cell extracts
EP2294187A2 (en) * 2008-05-21 2011-03-16 BioE LLC Differentiation of multi-lineage progenitor cells to pancreatic cells
US8663987B2 (en) 2008-05-28 2014-03-04 Ramot At Tel-Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
KR101903049B1 (en) 2008-08-20 2018-11-07 안트로제네시스 코포레이션 Treatment of stroke using isolated placental cells
KR20110050521A (en) 2008-08-20 2011-05-13 안트로제네시스 코포레이션 Improved cell composition and methods of making the same
KR20110050688A (en) 2008-08-22 2011-05-16 안트로제네시스 코포레이션 Methods and compositions for treatment of bone defects with placental cell populations
AU2009316541B2 (en) 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
GB0822246D0 (en) * 2008-12-05 2009-01-14 Reneuron Ltd Composition
CN102325878A (en) 2008-12-23 2012-01-18 斯特姆塞尔思加利福尼亚有限公司 Target populations of oligodendrocyte precursor cells and methods of making and using same
CN102369278A (en) * 2009-02-03 2012-03-07 学校法人庆应义塾 Culture method of embryoid bodies and/or neural stem cells derived from human differentiated cell-derived pluripotent stem cells
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
US9101570B1 (en) 2009-02-13 2015-08-11 Endocellutions, Inc. Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract
US9511093B2 (en) * 2009-03-23 2016-12-06 The Texas A & M University System Compositions of mesenchymal stem cells to regenerate bone
JP5783504B2 (en) * 2009-03-30 2015-09-24 国立研究開発法人国立環境研究所 Methods for assessing impact on embryonic programming
CA2760890C (en) 2009-05-08 2019-08-20 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
CA2767014C (en) 2009-07-02 2022-01-25 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
AU2010276201B2 (en) 2009-07-21 2013-10-17 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
EP2456860B1 (en) 2009-07-21 2018-09-05 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
ES2399711T3 (en) 2009-08-22 2013-04-02 The Board Of Trustees Of The University Of The Leland Stanford Junior University Obtaining images and evaluation of embryos, oocytes and stem cells
CN102725399B (en) 2009-12-18 2015-03-11 上海赛傲生物技术有限公司 Materials and methods for generating pluripotent stem cells
EP3284818B1 (en) 2010-01-26 2022-03-09 Celularity Inc. Treatment of bone-related cancers using placental stem cells
US8927276B2 (en) * 2010-02-17 2015-01-06 Cellin Technologies Oue Ex vivo progenitor and stem cell expansion and differentiation for use in the treatment of disease of the nervous system
SG10201501402UA (en) 2010-02-25 2015-04-29 Abt Holding Co Modulation of macrophage activation
KR20230054905A (en) 2010-04-07 2023-04-25 셀룰래리티 인코포레이티드 Angiogenesis using placental stem cells
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
PT2561078T (en) 2010-04-23 2018-12-03 Cold Spring Harbor Laboratory Novel structurally designed shrnas
AU2011249478B2 (en) 2010-05-06 2014-12-04 Regenics As Use of cellular extracts for skin rejuvenation
ES2666746T3 (en) 2010-07-13 2018-05-07 Anthrogenesis Corporation Methods to generate natural cytolytic lymphocytes
AU2011282642B2 (en) 2010-07-28 2015-06-11 Shinn-Zong Lin Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2012022725A2 (en) * 2010-08-19 2012-02-23 F. Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
WO2012034070A1 (en) 2010-09-09 2012-03-15 The Board Of Trustees Of The Leland Stanford Junior University Use of liposomal wnt compositions to enhance osseointegration
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012116185A1 (en) 2011-02-23 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting aneuploidy in human embryos
WO2012164137A1 (en) 2011-05-30 2012-12-06 Fundación Investigación En Regeneración Del Sistema Nervioso Stem cells and neural crest cells derived from olfactory ensheathing glia, and uses thereof
PL2714059T3 (en) 2011-06-01 2019-04-30 Celularity Inc Treatment of pain using placental stem cells
PL2718416T3 (en) 2011-06-06 2020-05-18 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
EP2560008B1 (en) * 2011-08-18 2016-11-30 Korea Institute of Science and Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
EA029023B1 (en) 2011-10-11 2018-01-31 Вэксинекс, Инк. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
WO2013076726A1 (en) 2011-11-21 2013-05-30 Ramot At Tel-Aviv University Ltd. Stem cell-derived neural cells for cell therapy in neurological disorders
JP6468843B2 (en) 2012-02-17 2019-02-13 ザ スキーペンズ アイ リサーチ インスティチュート Phenotypic profile of human retinal progenitor cells
CN102604894B (en) * 2012-02-29 2014-07-30 中国科学院广州生物医药与健康研究院 Culture medium for preparing neural stem cells and application thereof
WO2013150303A1 (en) 2012-04-03 2013-10-10 Reneuron Limited Stem cell microparticles
GB201302468D0 (en) 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product
EP2840133B1 (en) 2012-04-18 2017-06-14 Jeong Chan Ra Method for manufacturing stem cell having appropriate size for intravascular administration
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CA2875038A1 (en) 2012-05-31 2013-12-05 Auxogyn, Inc. In vitro embryo blastocyst prediction methods
KR101523040B1 (en) * 2012-06-26 2015-05-26 라정찬 Method for Preparing High Concentration of Stem Cells
KR20150059168A (en) 2012-07-19 2015-05-29 레뉴런 리미티드 Stem cell microparticles
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
US10357517B1 (en) 2012-10-01 2019-07-23 University Of South Florida Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592
EP3459522B1 (en) 2012-12-10 2021-02-17 Regenics AS Use of egg cellular extracts for wound treatment
ES2755878T3 (en) 2013-02-01 2020-04-24 Ares Trading Sa Abnormal phenotypes of singamia observed with imaging at pre-established time intervals for early identification of embryos with inferior development potential
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
US20160002597A1 (en) 2013-02-12 2016-01-07 Reneuron Limited Method of producing microparticles
ES2827250T3 (en) 2013-04-12 2021-05-20 Houston Methodist Hospital Improvement of organs for transplantation
DK2992088T3 (en) 2013-04-30 2019-11-11 Univ Leuven Kath CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
GB201317889D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product and use
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
ES2837840T3 (en) 2014-03-20 2021-07-01 Ares Trading Sa Quantitative measurement of developmental kinetics of human morula and blastocyst morphology
ES2945588T3 (en) 2014-08-26 2023-07-04 Univ Leland Stanford Junior Stem cell engraftment with a combination of a stem cell-targeted agent and modulation of immunoregulatory signaling
KR20190060016A (en) 2014-10-20 2019-05-31 뉴럴스템, 인크. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
CN105420105B (en) * 2015-12-25 2017-11-17 北京工业大学 Biochip and its manufacture method
US20190216891A1 (en) 2016-03-06 2019-07-18 Yeda Research And Development Co., Ltd. Method for modulating myelination
US10513689B2 (en) 2016-04-29 2019-12-24 Hope Biosciences, Llc Culture media for multipotent stem cells
IL301075B1 (en) 2017-01-30 2024-01-01 Univ Leland Stanford Junior A non-genotoxic conditioning regimen for stem cell transplantation
GB201919021D0 (en) 2019-12-20 2020-02-05 Reneuron Ltd Nucleic acid constructs for delivering polynucleotides into exosomes
CN115698262A (en) 2020-03-30 2023-02-03 阿卜杜拉国王科技大学 Compositions and methods for controlling cell identity
CN112080470B (en) * 2020-09-14 2022-07-12 中国科学院遗传与发育生物学研究所 In-vitro culture method for differentiation of neural stem cells into neurons
GB202114441D0 (en) 2021-10-08 2021-11-24 Reneuron Ltd Proteins and extracellular vesicles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009119A1 (en) * 1992-10-16 1994-04-28 Neurospheres Ltd. Remyelination using neural stem cells
WO1994016718A1 (en) * 1991-07-08 1994-08-04 Neurospheres Ltd. Genetic modification of neural stem cells
WO1996009543A1 (en) * 1994-09-23 1996-03-28 Neurospheres Holdings Ltd. In vitro models of cns function and dysfunction
WO1996015226A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753635A (en) * 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
NZ226750A (en) * 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4980174A (en) * 1988-12-23 1990-12-25 Jacqueline Sagen Method for alleviating depression
AU6174490A (en) * 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
WO1991009936A1 (en) * 1989-12-26 1991-07-11 Hana Biologics, Inc. Proliferated neuron progenitor cell product and process
US5411883A (en) * 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
GB9003791D0 (en) * 1990-02-20 1990-04-18 Ludwig Inst Cancer Res Transgenic animals,cell lines therefrom,and their use
AU7781991A (en) * 1990-04-26 1991-11-27 Schering Corporation Diastereoselective process for preparing n-substituted amino acids and derivatives
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
AU665012B2 (en) * 1991-07-08 1995-12-14 Neurospheres Holdings Ltd Novel growth factor-responsive progenitor cells which can be proliferated (in vitro)
US5175103A (en) * 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
WO1993009802A2 (en) * 1991-11-22 1993-05-27 Genentech, Inc. Tgf-beta to improve neural outcome
US5672499A (en) * 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
PT669973E (en) * 1992-10-28 2003-06-30 Neurospheres Holdings Ltd BIOLOGICAL FACTORS AND NEURAL ESTAMINAL CELLS
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5639618A (en) 1994-05-13 1997-06-17 Plurion, Inc. Method of isolating a lineage specific stem cell in vitro
JP2997995B2 (en) 1995-09-13 2000-01-11 日本コーンスターチ株式会社 Aqueous dispersion of biodegradable resin composition
WO1997016534A1 (en) * 1995-11-01 1997-05-09 Genentech, Inc. Normal neural epithelial precursor cells
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016718A1 (en) * 1991-07-08 1994-08-04 Neurospheres Ltd. Genetic modification of neural stem cells
WO1994009119A1 (en) * 1992-10-16 1994-04-28 Neurospheres Ltd. Remyelination using neural stem cells
WO1996009543A1 (en) * 1994-09-23 1996-03-28 Neurospheres Holdings Ltd. In vitro models of cns function and dysfunction
WO1996015226A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals

Also Published As

Publication number Publication date
US20060240553A1 (en) 2006-10-26
US6498018B1 (en) 2002-12-24
JP2009106301A (en) 2009-05-21
US20020164309A1 (en) 2002-11-07
US5968829A (en) 1999-10-19
EP1007636B1 (en) 2014-06-18
JP4848538B2 (en) 2011-12-28
AU758270B2 (en) 2003-03-20
WO1999011758A2 (en) 1999-03-11
US6777233B2 (en) 2004-08-17
CA2302484A1 (en) 1999-03-11
CA2302484C (en) 2013-12-24
AU9305998A (en) 1999-03-22
US20080107633A1 (en) 2008-05-08
JP2002518990A (en) 2002-07-02
EP1007636A2 (en) 2000-06-14
US6103530A (en) 2000-08-15

Similar Documents

Publication Publication Date Title
WO1999011758A3 (en) Cultures of human cns neural stem cells
AU6131198A (en) Isolated mammalian neural stem cells, methods of making such cells, and methods of using such cells
AU6039696A (en) Myogenic differentiation of human mesenchymal stem cells
AU1119397A (en) Ex vivo culture of stem cells
AU2730497A (en) Cryopreservation and extensive subculturing of human mesenchymal stem cells
CA2241266A1 (en) Enzyme composition for tissue dissociation
IL142094A0 (en) Methods of controlling proliferation and differentiation of stem and progenitor cells
AU7213294A (en) Methods of culturing and modulating the growth of hair follicular stem cells
AU5263198A (en) Antibiotic-producing strain of bacillus and methods for controlling plant diseases
AU5566396A (en) Manipulation of plant cell and tissue cultures
AU4330597A (en) Serum-free mammalian cell culture medium, and uses thereof
AU2001226395A1 (en) Techniques for growth and differentiation of human pluripotent stem cells
AU8128094A (en) (in vitro) amplification of stem cells
AU2192997A (en) Compositions and methods of making embryonic stem cells
CA2390281A1 (en) Hematopoietic differentiation of human embryonic stem cells
AU4369097A (en) Culturing of hematopoietic stem cells and their genetic engineering
HK1025052A1 (en) Method for the propagation of hair
AU4091297A (en) Antiparasitic agents
AU3392697A (en) (in vitro) derivation and culture of primate pluripotent stem cells and therapeutic uses thereof
AU6642994A (en) Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
AU1478000A (en) (in utero) transplantation of human mesenchymal stem cells
AU2197897A (en) Use of delta-like protein to inhibit the differentiation of stem cells
AU3813597A (en) Serum-free medium for growth of anchorage-dependant mammalian cells
AU5857398A (en) Receptacle for cell cultures and use of multiple dishes for culturing antitumour cells
AU3964799A (en) Compositions and methods for the characterization and transplantation of mammalian retinal stem cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2302484

Country of ref document: CA

Ref country code: CA

Ref document number: 2302484

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 93059/98

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 508770

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998945920

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998945920

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09486302

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 93059/98

Country of ref document: AU